SWK Holdings Corp is a specialty finance company that provides capital to life science businesses and engages in pharmaceutical development and licensing activities. The company focuses on earning royalties from the sales of licensed products, collecting interest and fees on secured debt, and pursuing development and commercialization of pharmaceutical compounds. It operates primarily through its finance receivables and pharmaceutical development segments to generate diversified income streams. SWK Holdings Corp is headquartered in the United States and serves a broad range of life science companies, institutions and inventors.

The company generates revenue primarily from owning or financing debt investments that produce royalties on life science product sales. It also earns interest and fees by advancing capital in the form of secured loans to life science companies. Pharmaceutical development, manufacturing, and licensing activities contribute another revenue stream, including collaborations such as the Aptar agreement. To a lesser extent, the company realizes capital appreciation from equity related investments and warrants in the life science sector.

The company organizes its operations into two distinct segments that reflect how management evaluates performance and allocates resources. These segments are Finance Receivables and Pharmaceutical Development. Each segment has its own revenue drivers and cost structure.

• Finance Receivables: This segment provides capital through debt investments, royalties, and secured loans to life science companies. It generates interest income, fees, and royalties from the sales of licensed products such as Besivance®, Forfivo XL®, Coflex®/Kybella®, Cambia®, Duo Royalty, Immune Globulin, Relief, and Iluvien®. The segment also includes term loans to companies like 4Web, Inc., AOTI, Inc., Elutia, Inc., Biotricity, Inc., CDMO Manufacturer, eTon Pharmaceuticals, Inc., Journey Medical Corporation, MedMinder Systems, Inc., MolecuLight, Inc., Nico Lifesciences, NeoLight, LLC, Shield Therapeutics, Plc, SKNV, Triple Ring, and ImpediMed.

• Pharmaceutical Development: This segment focuses on pharmaceutical development, manufacturing, and licensing activities. It includes collaborations such as the Aptar agreement to develop and commercialize new drug delivery systems and formulations. The segment also pursues internal research projects and seeks to license its technologies to third parties for royalty income.

SWK Holdings Corp maintains a diversified portfolio of floating rate debt investments in the life science sector, which positions it to benefit from rising interest rates. The company continuously monitors the short and long term financial position of its finance receivables portfolio to manage credit risk and sustain steady cash flow. Its focus on specialty financing for life science innovations provides a niche advantage in the market.

The company provides capital to firms such as 4Web, Inc., AOTI, Inc., Elutia, Inc., Biotricity, Inc., CDMO Manufacturer, eTon Pharmaceuticals, Inc., Journey Medical Corporation, MedMinder Systems, Inc., MolecuLight, Inc., Nico Lifesciences, NeoLight, LLC, Shield Therapeutics, Plc, SKNV, Triple Ring, and ImpediMed. It also earns royalties on products including Besivance®, Forfivo XL®, Coflex®/Kybella®, Cambia®, Duo Royalty, Immune Globulin, Relief, and Iluvien®. Equity related investments include holdings in AOTI common stock and Elutia common stock, among others. Warrant positions are held in companies such as Biotricity, Inc., eTon Pharmaceuticals, Inc., and Shield Therapeutics, Plc.